Heidelberg Pharma to Present New Clinical Data on ATAC Candidates at ASH 2026

Heidelberg Pharma will present new clinical data on its ATAC candidates, including the first recommended Phase 2 dose for pamlectabart tismanitin and early safety and efficacy for HDP-102, at the 2026 ASH Annual Meeting, highlighting progress in its Amanitin-based ADC pipeline.

Houston Metrowire Staff
••Healthcare
Heidelberg Pharma to Present New Clinical Data on ATAC Candidates at ASH 2026

Heidelberg Pharma AG will present new clinical data from its Phase I/IIa study of lead candidate pamlectabart tismanitin (HDP-101) in an oral presentation at the 68th Annual Meeting of the American Society of Hematology (ASH), taking place in New Orleans from December 12 to 15, 2026. The presentation will detail the recommended Phase 2 dose (RP2D) selection and preliminary antitumor activity in relapsed or refractory multiple myeloma (RRMM), according to the announcement distributed via NEWMEDIAWIRE.

The oral presentation, scheduled for Saturday, December 12, will be delivered by Professor Marc-Steffen Raab, MD, and will cover the first-in-human Phase 1/2a study of HDP-101, an amanitin-based BCMA-targeting antibody-drug conjugate (ADC). The Phase I dose-escalation portion, which included ten patient cohorts and was completed in April 2026, determined the RP2D for the Phase IIa expansion, which is now progressing as planned. Pamlectabart tismanitin demonstrated consistent clinical activity with a favorable safety profile in heavily pretreated RRMM patients, supporting its potential as a novel payload BCMA-targeted ADC therapy. The abstract is available in the ASH® ANNUAL PROGRAM.

In a poster session on Sunday, December 13, Dr. Irina Mocanu, MD, will present data on HDP-102, a first-in-class CD37-targeted amanitin-based ADC for relapsed or refractory B-cell malignancies. HDP-102 is designed to target CD37, which is overexpressed on B-cell lymphoma cells, and preclinical studies have shown excellent anti-tumor efficacy and good tolerability. In 2025, Heidelberg Pharma announced dosing of the first patient; three patients were treated at 40 µg/kg in the first cohort, with the treatment well tolerated and initial signs of biological activity observed even at that very low dose. Two patients showed stabilization of disease with regression and reduction of lymph nodes, and the safety committee recommended increasing the dose to 65 µg/kg in cohort 2. However, in line with Heidelberg Pharma’s strategic decision from September 2025 to discontinue the study, the company is exploring partnership opportunities to support continuation of the program. The abstract is available in the ASH® ANNUAL PROGRAM.

The data presentations matter because they provide the first clinical validation of Heidelberg Pharma’s ATAC technology, which uses Amanitin, a toxin derived from the green death cap mushroom, as a novel ADC payload. The RP2D selection for HDP-101 marks a critical milestone toward later-stage trials in multiple myeloma, a cancer with high unmet need, while the early HDP-102 results offer proof of concept for CD37 targeting in B-cell lymphomas. Together, these updates could strengthen the company’s position in partnering discussions for its pipeline, which also includes preclinical candidates HDP-103 for metastatic castration-resistant prostate cancer and HDP-104 for gastrointestinal tumors. With the ASH meeting serving as a global stage for hematology research, the presentations may attract interest from potential collaborators and investors. More information about Heidelberg Pharma is available at http://www.heidelberg-pharma.com/.

Blockchain Registration

QR Code for Blockchain Registration